erlotinib hydrochloride has been researched along with Benign Neoplasms in 204 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 80 (39.22) | 29.6817 |
| 2010's | 107 (52.45) | 24.3611 |
| 2020's | 17 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas Bukhari, SN; Abdel-Aziz, M; Abdel-Rahman, HM; Abdelazeem, AH; El-Sherief, HAM; Youssif, BGM | 1 |
| Dang Thi, TA; Dinh, TV; Hoang Thi, P; Le Duc, T; Le Thi, TA; Le-Nhat-Thuy, G; Nguyen Quang, H; Nguyen Thanh, P; Nguyen Thi, N; Nguyen, HT; Nguyen, TV; Pham-The, H | 1 |
| Adashek, JJ; Brown, EJ; Fu, S; Hong, DS; Karp, DD; Kato, S; Nguyen, L; Piha-Paul, SA; Subbiah, V; Sun, M; Yap, TA | 1 |
| Chan, ECY; Cheong, EJY; Chin, SY; Ng, DZW; Wang, Z | 1 |
| Ivanova, S; Tsvetkova, D | 1 |
| Abdel-Aziz, NI; El-Gohary, NS; El-Sayed, SM; El-Subbagh, HI; Ghaly, MA; Mansour, NI | 1 |
| Çoşut, B; Doğan, HA; Eçik, ET; Gül, EY; Karataş, EA; Karataş, ÖF | 1 |
| Barry, W; Berlin, S; Birrer, MJ; Campos, S; Colella, T; Hang, L; Horowitz, N; Krasner, C; Liu, J; Lundquist, C; Matulonis, U; Penson, R; Shoni, M; Whalen, C; Zarwan, C | 1 |
| Dai, X; Fu, H; Lin, J; Wang, Y; Zhao, Q; Zheng, Y; Zhu, C | 1 |
| Baitharu, I; Ekka, NJ; Mir, SA; Muhammad, A; Naik, PK; Nayak, B; Padhiary, A | 1 |
| Bayoumi, WA; El-Messery, SM; Nasr, MNA; Takla, FN | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
| Brors, B; Haibe-Kains, B; Kurilov, R | 1 |
| Nakamura, S; Ohira, A; Takai, Y; Tamura, M | 1 |
| Govindan, R; Larson, S; Lockhart, AC; Luo, J; Morgensztern, D; Park, H; Suresh, R; Tan, B; Trikalinos, NA; Van Tine, BA; Wang-Gillam, A; Waqar, S; Williams, K | 1 |
| Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH | 1 |
| Eissa, AAM; Fahim, SH; Gamal, MA; Nissan, YM; Ragab, FA; Salem, MA | 1 |
| Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG | 1 |
| Burris, HA; Clemett, D; Cohen, RB; Curt, G; Emeribe, U; Infante, JR; Kim, KB; LoRusso, PM; Tomkinson, HK | 1 |
| Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Steffens, M; Stingl, J | 1 |
| Kuo, KY; Kwong, B; Rahman, Z | 1 |
| Abraham, E; Albright, C; Alistar, AT; Bitting, RL; Blackstock, W; Chen, K; D'Agostino, RB; Desnoyers, RJ; DeYoung, B; Foley, KL; Goodman, M; Grant, SC; Kytola, V; Levine, EA; Nykter, M; Pagni, M; Pasche, B; Petro, RM; Petty, WJ; Porosnicu, M; Powell, BL; Qasem, SA; Robinson, M; Staren, ED; Thomas, A; Topaloglu, U; Vatca, M; Yang, M; Zhang, W | 1 |
| Adessi, C; Bossenmaier, B; Calles, A; Ceppi, M; Cervantes, A; De Jonge, MJ; Dua, R; Felip, E; Fleitas, T; Han, JY; Jacob, W; James, I; Kim, SW; Langenberg, MHG; Lassen, UN; Lolkema, MP; Martinez-Garcia, M; Mau-Sorensen, M; Meneses-Lorente, G; Meulendijks, D; Michielin, F; Nguyen, M; Schellens, JHM; Sleijfer, S; Steiner, L; Taus, A; Thomas, M; Vega-Harring, S; Voest, EE; Weisser, M; Wilson, S | 1 |
| Cheng, X; Han, J; He, J; Huang, W; Xiong, C; Zhu, H; Zhu, Z | 1 |
| Allard, M; Bellesoeur, A; Blanchet, B; Cardoso, E; Rousseau, B | 1 |
| Covell, DG | 1 |
| Bowles, DW; Lackner, MR; Leong, S; Moss, RA; Schellens, JHM; Schutzman, JL; Shankar, G; Spoerke, JM; van der Noll, R; Voest, EE; Ware, JA; Zhou, J | 1 |
| Cho, H; Levy, D | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Cheung, YK; Lee, SM; Ursino, M; Zohar, S | 1 |
| Chandra, R; Singh, I; Singh, S; Uversky, VN; Verma, V | 1 |
| Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F | 1 |
| Arora, N; Gavya S, L; Ghosh, SS | 1 |
| Dekker, H; Labots, M; Meijer, GA; Pham, TV; Ruijter, R; Van der Hoeven, JJM; Van der Mijn, JC; Van der Vliet, HJ; Verheul, HMW | 1 |
| Adjei, A; Allred, J; Goetz, M; Jazieh, K; Kaufmann, SH; Lim, VS; Molina, J; Reid, J; Yin, J | 1 |
| Chen, CH; DasGupta, R; Lam, PYP; Miller, MA; Ng, EX; Sun, G; Wei, SC | 1 |
| Asano, M; Boku, N; Fujiwara, Y; Higashiyama, A; Inoue, A; Inoue, Y; Kanda, S; Kikuchi, K; Mizutani, H; Mori, T; Nakai, Y; Nozawa, K; Ohe, Y; Taguchi, O; Takahashi, M; Takashima, A; Yamazaki, N | 1 |
| Bernatchez, JA; Li, J; Li, R; Luan, Y | 1 |
| Chen, Y; Gu, Y; Jiang, X; Liu, Y | 1 |
| Chen, D; Chen, J; Huo, B; Li, D; Song, M; Xue, J; Yuan, G; Zhang, F; Zhao, X | 1 |
| Amini, A; Bhardwaj, V; Cascone, T; Cortez, MA; Evans, J; Heymach, JV; Komaki, RU; Welsh, JW | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Berger, W; Ferk, F; Heffeter, P; Hoda, MA; Jungwirth, U; Karnthaler-Benbakka, C; Knasmüller, S; Kowol, CR; Kryeziu, K | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Bichsel, KJ; Forney, E; Gogia, N; Hammiller, B; Hansen, LA; Malouff, T; Pena, Z; Watson, P | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Bai, S; Bothos, J; Damico-Beyer, LA; Davis, JD; Eppler, S; Jin, D; Joshi, A; Kaur, S; Nijem, I; Patel, P; Peterson, A; Xin, Y | 1 |
| Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C | 1 |
| Amberg, N; Ansari, P; Boelke, E; Buhren, BA; Fischer, JW; Gerber, PA; Harder, J; Holcmann, M; Homey, B; Kislat, A; Lichtenberger, BM; Mackenzie, C; Röck, K; Schröder, JM; Schrumpf, H; Sibilia, M; Smolle, V; Wollenberg, A | 1 |
| Huang, Q; Li, J; Liu, JY; Xue, JP; Zhang, FL; Zheng, K | 1 |
| Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Blakely, LJ; Schwartzberg, LS; Smiley, LM; Stewart, CF; Tagen, M; Tauer, KW | 1 |
| Benhadji, KA; Brail, LH; Bumgardner, W; Cohen, EE; Hollebecque, A; Houédé, N; Italiano, A; Massard, C; Miller, J; Soria, JC; Westwood, P | 1 |
| Cohen, RB; Engelman, JA; Felip, E; Jänne, PA; Laird, AD; Macé, S; Martinez, P; Rockich, K; Ruiz-Soto, R; Shapiro, GI; Xu, J | 1 |
| Calvert, H; Fettner, S; Hamilton, M; Ling, J; Lum, BL; Pantze, M; Plummer, R; Rakhit, A; Ranson, M; Twelves, C | 1 |
| Buclin, T; Decosterd, LA; Gairard-Dory, AC; Gourieux, B; Guidi, M; Petit-Jean, E; Quoix, E; Ubeaud-Séquier, G; Widmer, N | 1 |
| Cotreau, MM; Han, M; Hofmeister, CC; Isaacs, R; Jac, J; Papadopoulos, KP; Patnaik, A; Payumo, FC; Ramanathan, RK; Tibes, R; Tolcher, A; Weiss, GJ | 1 |
| Allen, EJ; Garbett, SP; Leander, R; Quaranta, V; Tyson, DR | 1 |
| De, S; Dermawan, JK; Stark, GR | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Adema, AD; Avan, A; Hoebe, EK; Huijts, CM; Peters, GJ; Ruijtenbeek, R; Veal, GJ; Wosikowski, K | 1 |
| Anderson, KS; Apetri, M; Kim, Y; Luo, B; Settleman, JE | 1 |
| Ackley, E; Balak, M; Bhang, HE; Caushi, JX; Chiang, DY; Cooke, VG; Hims, MM; Kao, I; Keen, N; Korn, JM; Krishnamurthy Radhakrishna, V; Leary, RJ; Michor, F; Palmer, M; Rakiec, D; Raza, A; Ruddy, DA; Schlabach, MR; Sellers, WR; Shaw, P; Singh, AP; Stegmeier, F; Zhao, R | 1 |
| Chariot, A; Shostak, K | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Bessarabova, M; Dorner, A; Gulbekyan, G; Hope, A; Kolpakova-Hart, E; Li, B; Merberg, D; Nikolsky, Y; Pustovalova, O; Schu, M; Shin, H; Trepicchio, WL | 1 |
| Ji, SG; Li, MC; Lin, PP; Liu, J; Liu, L; Liu, LK; Wang, CY; Wang, PP; Xu, X; Zhang, B; Zhao, LY | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Arzt, J; Busman, TA; Holen, KD; Kirschbrown, W; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA | 1 |
| Cameron, MG; Kersten, C; Laird, B; Mjåland, S | 1 |
| Coronado, C; Dios, JL; Fernández-García, EM; Goel, S; Miguel-Lillo, B; Morán, T; Rosell, R; Viteri, S | 1 |
| Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
| Dimitroulakos, J; Goss, GD; Jonker, DJ; la Porte, C; Laurie, SA; Oza, AM; Spaans, JN; Weberpals, JI | 1 |
| Capparelli, EV; Kurzrock, R; Lam, LH | 1 |
| Doi, T; Enatsu, S; Kojima, T; Nakamura, T; Ohmatsu, H; Takahashi, H; Turner, K; Uenaka, K; Wacheck, V; Yoh, K; Zenke, Y | 1 |
| Jiang, L; Shen, C; Yu, W; Zhang, P | 1 |
| Basch, EM; Green, AK; Wood, WA | 1 |
| Bourhis, J; Castadot, P; Chargari, C; Deutsch, E; Ghalibafian, M; Haie-Meder, C; Magné, N; Soria, JC | 1 |
| Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A | 1 |
| Calvo, E; Chen, H; Dancey, JE; Lin, CC; Mays, T; Mita, AC; Mita, MM; O'Rourke, P; Papadopoulos, KP; Patnaik, A; Preston, GG; Rodon, J; Sarantopoulos, J; Takimoto, CH; Tolcher, AW; Yeh, IT | 1 |
| Fu, H; Hawk, N; Kauh, J; Khuri, FR; Ramalingam, SS; Sun, SY; Wang, X; Yue, P | 1 |
| Jatoi, A; Nguyen, PL | 1 |
| Balko, JM; Black, EP | 1 |
| Bangerter, M; Brudler, O; Heinrich, B; Reimer, G | 1 |
| Brahmer, JR; Ettinger, DS; Finckenstein, FG; Guarino, MJ; Hosford, MA; Lu, H; Philip-Norton, RE; Rudin, CM; Schneider, CJ; Weber, MR | 1 |
| Jones, D | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Cheung, YK | 1 |
| Chen, ZG; Huang, DH; Khuri, FR; Peng, XH; Shin, DM; Su, L; Zhang, H | 1 |
| Carlson, RH | 1 |
| de Castro, J; García-Campelo, R; Isla, D; Provencio, M | 1 |
| Chen, P; Chen, ZG; Du, Y; Fu, H; Khuri, FR; Li, L; Li, Z; Shin, DM; Sun, SY | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| Carbone, DP; Chen, X; Dang, TP; Konishi, J; Vo, H; Yi, F | 1 |
| Carter, CA; Giaccone, G; Kelly, RJ | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Geissler, M; Steins, M; Thomas, M | 1 |
| Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A | 1 |
| Bandarchi-Chamkhaleh, B; Chen, EX; Do, T; Duran, I; Le Tourneau, C; MacLean, M; Mak, TW; Metser, U; Nayyar, R; Pham, NA; Quintela-Fandino, M; Siu, LL; Tsao, M; Tusche, MW; Wang, L; Wright, JJ | 1 |
| Buie, L; Chiu, WK; Davies, JM; Dees, EC; Irvin, W; Ivanova, A; Keller, K; O'Neil, BH; Sanoff, HK; Stinchcombe, TE; Walko, C | 1 |
| Dalhaug, A; Nieder, C | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Dunn, EF; Harari, PM; Wheeler, DL | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ | 1 |
| Dakhil, SR; Flynn, PJ; Jatoi, A; Loprinzi, CL; Mattar, BI; Nikcevich, DA; Novotny, P; Sekulic, A; Sloan, JA; Thrower, A; Wentworth-Hartung, NL | 1 |
| Bendell, JC; Blobe, GC; Broadwater, G; Bullock, KE; Gockerman, JP; Howard, LA; Hurwitz, HI; Lager, JJ; Meadows, KL; Morse, MA; O'Neill, MM; Petros, WP; Truax, R; Uronis, HE; Younis, I; Zafar, SY | 1 |
| Haramoto, M; Horibe, T; Kawakami, K; Kohno, M; Matsuzaki, K; Nakajima, O; Ohara, K; Yano, Y | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Doussau, A; Le Tourneau, C; Ollivier, L; Paoletti, X; Postel-Vinay, S; Servois, V | 1 |
| Anderson, A; Gilmer, TM; Greger, J; Liu, L; Liu, Y; Martin, AM; Peterson, J; Shi, H | 1 |
| Azria, D; Bascoul-Mollevi, C; Bazin, H; Chardès, T; Crapez, E; Gaborit, N; Larbouret, C; Mathis, G; Pèlegrin, A; Peyrusson, F; Poul, MA; Vallaghe, J | 1 |
| Geoerger, B; Leblond, P | 1 |
| Adjei, AA; Garmey, E; Schwartz, B | 1 |
| Curtit, E; Mansi, L; Viel, E; Vignot, S | 1 |
| Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO | 1 |
| Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C | 1 |
| Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA | 1 |
| Belani, C; Boinpally, R; Evans, J; Franke, A; Gail Eckhardt, S; Haluska, P; Leong, S; O'Bryant, CL; Ramalingam, S; Ramanathan, RK; Rosen, L; Venugopal, B; Witt, K | 1 |
| Boeck, S; Heinemann, V; Kächele, V; Parmar, S; Paul, T; Rüdiger, S; Schumann, C; Seeringer, A; Seufferlein, T; Stingl, JC | 1 |
| Chhatwani, L; Colevas, AD; Decker, R; Fisher, GA; Krupitskaya, Y; Latz, JE; Padda, SK; San Pedro-Salcedo, M; Wakelee, HA | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F | 1 |
| Daw, HA; Peerzada, MM; Spiro, TP | 1 |
| Anderes, K; Bliesath, J; Bunag, D; Drygin, D; Ho, C; Huser, N; Lim, JK; O'Brien, SE; Omori, M; Proffitt, C; Rice, WG; Ryckman, DM; Siddiqui-Jain, A; Streiner, N | 1 |
| Craven, RJ; Jin, L; Mir, SU | 1 |
| Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M | 1 |
| Balu-Iyer, SV; Iyer, V; O'Connor, R; Straubinger, RM; Trummer, BJ | 1 |
| Chai, F; Ferrari, D; Garmey, EG; Goldman, JW; Just, RG; Laux, I; Rosen, LS; Savage, RE | 1 |
| Antoniou, C; Katsambas, A; Nikolaou, V; Stratigos, A; Strimpakos, AS; Syrigos, KN | 1 |
| Brown, HA; Bruntz, RC; Bryson, BL; Cipriano, R; Graham, J; Jackson, MW; Miskimen, KL; Scott, SA; Stark, GR | 1 |
| Ho, WL; Wong, H; Yau, T | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Guevara, T; Orzáez, M; Pérez-Payá, E; Sancho, M | 1 |
| Brock, K; Evans, TR; Gedrich, R; Hopkins, CA; Macpherson, IR; Poondru, S; Simon, GR; Stephens, A; Stewart, K | 1 |
| Lou, D; McCormick, F; Young, A | 1 |
| Aneja, M; Berg, SR; Cella, D; Gandhi, M; Hlubocky, FJ; Lacouture, ME; Wagner, LI; Webster, K | 1 |
| Basti, S; Borkar, DS; Lacouture, ME | 1 |
| Couzin, J | 1 |
| Kim, TE; Murren, JR | 1 |
| Albanell, J; Baselga, J | 1 |
| Bianco, C; De Luca, A; Maiello, MR; Normanno, N; Salomon, DS | 1 |
| Grünwald, V; Hidalgo, M | 1 |
| Bulgaru, AM; Goel, S; Mani, S; Perez-Soler, R | 1 |
| Bacus, S; Brattain, MG; deGraffenried, L; Hammond, LA; Hidalgo, M; Kreisberg, JI; Malik, SN; Rizzo, J; Rowinsky, EK; Siu, LL | 1 |
| Garber, K | 2 |
| Maneely, D | 1 |
| Giaccone, G; Janmaat, ML | 1 |
| Ciardiello, F; De Placido, S; De Vita, F; Orditura, M; Tortora, G | 1 |
| Pérez-Soler, R | 1 |
| El-Rayes, BF; LoRusso, PM | 1 |
| Ginsburg, GS; Hortobagyi, GN; Linette, GP; Pietrusko, R; Pusztai, L; Rolfe, M; Ross, JS; Schenkein, DP; Stagliano, NE; Stec, J; Symmans, WF | 1 |
| Biddle, A; Davis, TH; Desai, NB; Dmitrovsky, E; Dragnev, KH; Hamilton, M; Iwata, KK; Ma, Y; Memoli, N; Memoli, VA; Nugent, WC; Petty, WJ; Rigas, JR | 1 |
| Harari, PM | 1 |
| Dai, Q; Iwata, KK; Kroog, G; Lia, M; Ling, YH; Perez-Soler, R; Zou, YY | 1 |
| Faj, D; Kurbel, S | 1 |
| Albanell, J; Gascón, P | 1 |
| Blum, HE; Geissler, M; Grimm, CF | 1 |
| Chosidow, O; Dirschka, T; Elsner, J; Layton, A; Mancini, L; Maughan, T; Morere, JF; Santoro, A; Segaert, S; Sobrero, A; Tabernero, J; Van Cutsem, E | 1 |
| Peréz-Soler, R; Saltz, L | 1 |
| Elsner, J; Gutzmer, R; Kapp, A; Werfel, T | 1 |
| Bates, SE; Fojo, T | 1 |
| Ciardiello, F; De Vita, F | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| D'Orazio, A; Reddy, K | 1 |
| Sun, Y; Wang, Y | 1 |
| Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Sipples, R | 1 |
| Baselga, J | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Tuma, RS | 1 |
| Bruno, R; Eppler, SM; Hamilton, M; Lu, JF; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Baselga, J; Mendelsohn, J | 1 |
| Calarese, P; Morse, L | 1 |
| Alomar, A; Capdevila, J; García Muret, MP; Marcuello, E; Pallarés, C; Roé, E | 1 |
| Marshall, J | 1 |
| Morse, L | 1 |
| Curtiss, FR | 1 |
| Cognetti, F; Di Segni, S; Fontana, A; Gelibter, AJ; Labianca, R; Lonardi, S; Loupakis, F | 1 |
| Liu, TH | 1 |
| Beeram, M; Hamilton, M; Hammond, LA; Hidalgo, M; Kreisberg, JI; Mita, MM; Nadler, P; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Wolf, J; Wood, D | 1 |
| Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J | 1 |
| Baker, SD; Bates, SE; Brahmer, J; Cusatis, G; Hidalgo, M; Li, J; Robey, RW; Sparreboom, A | 1 |
| Dutta, PR; Maity, A | 1 |
| Ben-Porat, L; Chapman, PB; Dickler, MN; Panageas, KS; Schrag, D | 1 |
| Chen, Z; Gonzalez, KD; Gu, D; Hill, KA; Li, K; Saldivar, JS; Scaringe, WA; Sommer, SS | 1 |
| Fujisaka, Y; Horiike, A; Murakami, H; Shimoyama, T; Tamura, T; Yamada, Y; Yamamoto, N | 1 |
| Edelman, MJ; Hohl, RJ; Hollis, DR; Kindler, HL; Lewis, LD; Lichtman, SM; Marshall, JL; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA | 1 |
| Chen, EX; Dancey, J; Duan, L; Duran, I; Hirte, H; Hotté, SJ; Lathia, C; MacLean, M; Pond, GR; Siu, LL; Turner, S; Walsh, S; Wright, JJ | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS | 1 |
| Miller, JD | 1 |
| Al Omari, AS; Chiorean, EG; Fife, KL; Foster, AE; Jones, DR; Murry, DJ; Porter, JM; Strother, RM; Sweeney, CJ; Yoder, CA; Yu, M | 1 |
| Giordano, S; Petrelli, A | 1 |
| Heymann, WR | 1 |
| Fojo, T | 1 |
| Ciardiello, F; Tortora, G | 1 |
57 review(s) available for erlotinib hydrochloride and Benign Neoplasms
| Article | Year |
|---|---|
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Erlotinib Hydrochloride; Humans; Neoplasms | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
Topics: Binding Sites; Catalytic Domain; Drug Design; Erlotinib Hydrochloride; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases | 2019 |
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy.
Topics: Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Movement; DNA Damage; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyridines; Pyrrolidinones; Quinazolines; Quinolines; Radiation Tolerance; Signal Transduction; Up-Regulation | 2013 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Infant; Male; Middle Aged; Neoplasms; Quinazolines; Young Adult | 2015 |
EGFR and NF-κB: partners in cancer.
Topics: Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proteins; Quinazolines; Signal Transduction | 2015 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Counseling; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Neoplasms; Panitumumab; Quinazolines | 2008 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphoma; Male; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
Small-molecule inhibitors of the human epidermal receptor family.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Cutaneous side effects of EGFR inhibitors--appearance and management].
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2010 |
Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
[Dose finding methods for targeted agents: new perspectives].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
[EGFR/HER1: a target life].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins | 2012 |
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arterial Occlusive Diseases; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Neoplasms; Panitumumab; Quinazolines; Randomized Controlled Trials as Topic; Risk; Venous Thromboembolism | 2012 |
Pulmonary toxicities of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2011 |
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab | 2013 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Erlotinib OSI/Roche/Genentech.
Topics: Animals; Clinical Trials as Topic; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2002 |
Epithelial growth factor receptor interacting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays | 2002 |
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2003 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase.
Topics: Animals; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2003 |
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Cell Differentiation; Cell Movement; Cell Survival; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; History, Modern 1601-; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2003 |
HER1/EGFR targeting: refining the strategy.
Topics: Antineoplastic Agents; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction | 2004 |
Targeting the epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Targeted therapies for cancer 2004.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Bevacizumab; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gemtuzumab; Humans; Neoplasms; Pharmacogenetics; Quinazolines; Rituximab; Trastuzumab | 2004 |
Epidermal growth factor receptor inhibition strategies in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Small molecules with EGFR-TK inhibitor activity.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction | 2005 |
[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, abl; Humans; Imatinib Mesylate; Neoplasms; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2005 |
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2005 |
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2005 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
Common side effects of anti-EGFR therapy: acneform rash.
Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Epidermal growth factor receptor targeting in cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
EGFR-targeted therapy and related skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Humans; Ichthyosis; Middle Aged; Neoplasms; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pruritus; Quinazolines; Signal Transduction; Skin Care; Trastuzumab | 2006 |
Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Models, Biological; Neoplasms; Quinazolines; Signal Transduction | 2006 |
Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Communication; Cetuximab; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Forecasting; Gefitinib; Humans; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Care Planning; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
Topics: Antineoplastic Agents; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morphogenesis; Neoplasm Invasiveness; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Commentary: Novel therapies for cancer: why dirty might be better.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2 | 2008 |
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2001 |
44 trial(s) available for erlotinib hydrochloride and Benign Neoplasms
| Article | Year |
|---|---|
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Glycine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; NF-kappa B | 2022 |
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Erlotinib Hydrochloride; Humans; Neoplasms; Paclitaxel | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Phosphatidylinositol 3-Kinase; Sirolimus; Treatment Outcome | 2021 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib | 2021 |
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Sirolimus | 2017 |
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasms; Neuregulin-1; Receptor, ErbB-3; Survival Analysis; Treatment Outcome | 2017 |
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides | 2017 |
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinolones; Salvage Therapy; Tissue Distribution | 2019 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cross-Over Studies; Double-Blind Method; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Male; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Erlotinib Hydrochloride; Genotype; Humans; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Topotecan | 2014 |
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Everolimus; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Time Factors; Treatment Outcome; Vomiting | 2014 |
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinoxalines; Safety; Sulfonamides; Survival Rate; Tissue Distribution; TOR Serine-Threonine Kinases | 2014 |
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breath Tests; Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Erythromycin; Female; Humans; In Vitro Techniques; Male; Microsomes, Liver; Midazolam; Middle Aged; Neoplasms; Quinazolines | 2014 |
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides | 2015 |
Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Panitumumab; Prospective Studies; Quinazolines; Recurrence; Young Adult | 2015 |
Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Depsipeptides; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2016 |
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Rosuvastatin Calcium; Treatment Outcome | 2016 |
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2016 |
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasms; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines | 2009 |
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Biomarkers, Pharmacological; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2010 |
A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Phenotype; Quinazolines; Treatment Outcome; Vinblastine | 2011 |
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Medication Adherence; Middle Aged; Neoplasms; Quality of Life; Quinazolines; Sunscreening Agents | 2010 |
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2011 |
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prodrugs; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult | 2011 |
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver; Liver Function Tests; Male; Middle Aged; Neoplasm Invasiveness; Neoplasms; Protein Binding; Quinazolines | 2012 |
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Quinazolines | 2012 |
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib | 2012 |
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2012 |
A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinolines; Thiophenes; Tissue Distribution | 2013 |
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Topics: Adult; Aged; Algorithms; Analysis of Variance; Area Under Curve; Biotransformation; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasms; Population; Protein Kinases; Quinazolines | 2006 |
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Skin | 2006 |
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2007 |
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Topics: Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Half-Life; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 2008 |
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kidney Diseases; Kidney Function Tests; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2007 |
A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2008 |
104 other study(ies) available for erlotinib hydrochloride and Benign Neoplasms
| Article | Year |
|---|---|
Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Structure-Activity Relationship; Triazoles | 2018 |
Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.
Topics: Amino Acid Sequence; Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Quinazolines; Sequence Alignment; Structure-Activity Relationship; Triazoles | 2018 |
Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism.
Topics: Cytochrome P-450 CYP3A; Drug Interactions; Erlotinib Hydrochloride; Humans; Ketoconazole; Models, Biological; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Rivaroxaban; Venous Thromboembolism | 2022 |
New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Phthalimides; Protein Kinase Inhibitors; Structure-Activity Relationship | 2022 |
Erlotinib-Modified BODIPY Photosensitizers for Targeted Photodynamic Therapy.
Topics: Erlotinib Hydrochloride; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Reactive Oxygen Species | 2023 |
Xijiao Dihuang decoction relieves the erlotinib-induced dermatitis.
Topics: Animals; Chemokines; Cytokines; Dermatitis; Erlotinib Hydrochloride; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasms; Quality of Life; Skin Diseases | 2023 |
Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches.
Topics: Antibodies; Drug Development; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Proteins; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms | 2023 |
Developing multitarget coumarin based anti-breast cancer agents: synthesis and molecular modeling study.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Coumarins; Doxorubicin; Erlotinib Hydrochloride; Neoplasms | 2023 |
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
A case report of pseudo-exfoliation syndrome with prolonged corneal epithelial regeneration because of erlotinib-induced unilateral corneal ulcer and anterior uveitis.
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Cornea; Corneal Topography; Corneal Ulcer; Erlotinib Hydrochloride; Exfoliation Syndrome; Humans; Male; Neoplasms; Uveitis, Anterior | 2020 |
Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents.
Topics: A549 Cells; Antineoplastic Agents; Breast Neoplasms; Coumarins; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; HCT116 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Solubility; Structure-Activity Relationship | 2021 |
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Biomarkers, Tumor; Calcifediol; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Survival Analysis | 2017 |
Mitigation of epidermal growth factor receptor inhibitor-induced side effects utilizing melanin and vascular-specific lasers: A case report series.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Immunological; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Hemoglobins; Humans; Hypertrichosis; Intense Pulsed Light Therapy; Lasers, Dye; Male; Melanins; Middle Aged; Neoplasms | 2017 |
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Clone Cells; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genes, erbB-1; Genes, Neoplasm; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Protein Kinase Inhibitors; Retrospective Studies; Sequence Analysis, DNA; Smoking | 2017 |
Common and uncommon adverse cutaneous reactions to erlotinib: a study of 20 Chinese patients with cancer.
Topics: Adult; Aged; Anaphylaxis; Antineoplastic Agents; Asian People; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Skin Diseases | 2018 |
[Therapeutic drug monitoring - 4th edition of the congress of pharmacology of anticancer drugs].
Topics: Antineoplastic Agents; Bayes Theorem; Bevacizumab; Colorectal Neoplasms; Drug Monitoring; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Liver; Neoplasms; Phenylurea Compounds; Pyridines | 2017 |
A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Cluster Analysis; Data Mining; Databases, Factual; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Linear Models; Microarray Analysis; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2017 |
Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Proliferation; Computer Simulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Neoplasm Recurrence, Local; Neoplasms; Phenotype; Time Factors; Tumor Microenvironment | 2018 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
Dose-finding designs for cumulative toxicities using multiple constraints.
Topics: Antineoplastic Agents; Biostatistics; Clinical Trials as Topic; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Models, Statistical; Neoplasms; Research Design | 2019 |
In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genetic Variation; Humans; Molecular Dynamics Simulation; Neoplasms; Protein Kinase Inhibitors | 2018 |
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Topics: Acrylamides; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Feeder Cells; Fluorescent Antibody Technique; Gene Expression; High-Throughput Screening Assays; Humans; Keratin-18; Keratin-8; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neoplasms; Piperazines; Precision Medicine; Primary Cell Culture; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2017 |
Multi-facet implications of PEGylated lysozyme stabilized-silver nanoclusters loaded recombinant PTEN cargo in cancer theranostics.
Topics: Antineoplastic Agents; Cell Proliferation; Disease Transmission, Infectious; Erlotinib Hydrochloride; Flow Cytometry; Humans; MCF-7 Cells; Microscopy, Confocal; Models, Biological; Muramidase; Neoplasms; PTEN Phosphohydrolase; Silver; Spectrometry, Fluorescence; Theranostic Nanomedicine | 2018 |
Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2018 |
Ultrafast Single-Cell Level Enzymatic Tumor Profiling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Databases, Factual; Erlotinib Hydrochloride; Flow Cytometry; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; High-Throughput Screening Assays; Humans; Lab-On-A-Chip Devices; Mice; Microfluidic Analytical Techniques; Neoplasms; Oligopeptides; Peptide Hydrolases; Proteolysis; Single-Cell Analysis | 2019 |
Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
Topics: Acneiform Eruptions; Adult; Afatinib; Aged; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Prognosis; Risk Factors; Skin; Water Loss, Insensible | 2019 |
Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor.
Topics: Allyl Compounds; Animals; Antineoplastic Agents; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Skin; Sulfides | 2019 |
Epidermal Growth Factor Receptor-Targeted Delivery of a Singlet-Oxygen Sensitizer with Thermal Controlled Release for Efficient Anticancer Therapy.
Topics: Animals; Cell Line, Tumor; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Injections, Intravenous; Mice; Neoplasms; Photochemotherapy; Photosensitizing Agents; Singlet Oxygen | 2019 |
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Topics: Acid Anhydride Hydrolases; Animals; Arsenic Trioxide; Arsenicals; BRCA1 Protein; DNA Breaks, Double-Stranded; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasms; Oxides; Phosphorylation; Quinazolines; Rad51 Recombinase; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
Topics: Alopecia; Animals; Antineoplastic Agents; Apoptosis; Cyclophosphamide; Disease Progression; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Hair Follicle; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53 | 2013 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Topics: Animals; Antineoplastic Agents; Chemokines; Cytokines; Dermatitis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Hair Follicle; Humans; Inflammation Mediators; Interleukin-1; Keratinocytes; Langerhans Cells; Lymphocytes; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neoplasms; Quinazolines; Skin; Translational Research, Biomedical | 2013 |
A novel strategy for targeting photodynamic therapy. Molecular combo of photodynamic agent zinc(II) phthalocyanine and small molecule target-based anticancer drug erlotinib.
Topics: Antineoplastic Agents; Drug Delivery Systems; Erlotinib Hydrochloride; Ethylene Glycol; Hep G2 Cells; Humans; Indoles; Isoindoles; Neoplasms; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Quinazolines; Zinc Compounds | 2013 |
The economic evaluation of personalised oncology medicines: ethical challenges.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
Derivation and experimental comparison of cell-division probability densities.
Topics: Antineoplastic Agents; Cell Count; Cell Cycle; Cell Division; Cell Proliferation; Cycloheximide; Dimethyl Sulfoxide; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Probability; Quinazolines; Stochastic Processes | 2014 |
EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.
Topics: Breast; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Humans; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOS1 Protein; Up-Regulation | 2014 |
Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Adducts; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Organoplatinum Compounds; Phosphorylation; Quinazolines; Signal Transduction | 2014 |
Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction; STAT5 Transcription Factor | 2015 |
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Crizotinib; DNA; DNA Barcoding, Taxonomic; DNA, Complementary; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gene Dosage; Gene Library; Humans; Lung Neoplasms; Models, Theoretical; Neoplasms; Oligonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA | 2015 |
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Models, Statistical; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Survival Analysis | 2015 |
Chronopharmacokinetics of Erlotinib and Circadian Rhythms of Related Metabolic Enzymes in Lewis Tumor-Bearing Mice.
Topics: Administration, Oral; Animals; Chronopharmacokinetics; Circadian Rhythm; Erlotinib Hydrochloride; Female; Liver; Mice; Mice, Inbred C57BL; Neoplasms; RNA, Messenger | 2016 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Interactions; Erlotinib Hydrochloride; Female; Histamine H2 Antagonists; Humans; Incidence; Male; Middle Aged; Neoplasms; Proton Pump Inhibitors; Retrospective Studies; Survival Rate | 2016 |
Synthesis and Biological Evaluation of Novel Carbohydrate-Derived Derivatives of Erlotinib.
Topics: A549 Cells; Antineoplastic Agents; Carbohydrates; Cell Line, Tumor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; MCF-7 Cells; Neoplasms; Structure-Activity Relationship | 2016 |
Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology.
Topics: Bevacizumab; Centers for Medicare and Medicaid Services, U.S.; Cetuximab; Erlotinib Hydrochloride; Formularies as Topic; Humans; Medical Oncology; Neoplasms; Off-Label Use; Protein Kinase Inhibitors; Review Literature as Topic; United States | 2016 |
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi | 2008 |
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2008 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
[EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Neoplasms; Quinazolines | 2008 |
Avastin-Tarceva combination fails in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2009 |
Selecting promising treatments in randomized Phase II cancer trials with an active control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials, Phase II as Topic; Control Groups; Endpoint Determination; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2009 |
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Lysosomes; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quantum Dots; Quinazolines; Signal Transduction | 2009 |
American Association for Cancer Research 100th Annual Meeting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Male; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research; Societies, Medical; United States; Vorinostat | 2009 |
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Erlotinib: potentially fatal in cases of liver failure: a contraindication.
Topics: Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Failure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor, Notch3; Receptors, Notch; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2010 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult | 2010 |
A novel hybrid peptide targeting EGFR-expressing cancers.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Mutant Chimeric Proteins; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2011 |
Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Topics: Anilides; Antibodies, Monoclonal; Apoptosis; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunoprecipitation; Lapatinib; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2011 |
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorescence Resonance Energy Transfer; Humans; Lapatinib; Mice; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptors, Fibroblast Growth Factor | 2011 |
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline | 2012 |
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines | 2013 |
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Naphthyridines; Neoplasms; Phenazines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1.
Topics: Acetylation; Acute-Phase Proteins; Animals; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Lipocalin-2; Lipocalins; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Nude; Models, Biological; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptors, Progesterone; Transcription Factor RelA; Transcription, Genetic; Transplantation, Heterologous; Tyrphostins | 2012 |
Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liposomes; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Spectrometry, Fluorescence | 2012 |
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azithromycin; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Pulse Therapy, Drug; Quinazolines; Retrospective Studies; Time Factors | 2012 |
FAM83B mediates EGFR- and RAS-driven oncogenic transformation.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Gene Knockdown Techniques; Humans; Mammary Glands, Human; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Sequence Data; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Structure, Tertiary; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases; Transcriptome | 2012 |
Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin A; Cyclin-Dependent Kinase 2; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2012 |
Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Mitogen-Activated Protein Kinases; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines | 2013 |
The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Health Status; Humans; Male; Middle Aged; Neoplasms; Qualitative Research; Quality of Life; Quinazolines; Surveys and Questionnaires | 2013 |
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Chicago; ErbB Receptors; Erlotinib Hydrochloride; Eye Diseases; Female; Follow-Up Studies; Gefitinib; Humans; Male; Medical Audit; Neoplasms; Panitumumab; Quinazolines; Retrospective Studies | 2013 |
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Topics: Administration, Oral; Antineoplastic Agents; Clinical Trials as Topic; Costs and Cost Analysis; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines; Treatment Outcome | 2003 |
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinases; Neoplasms; Quinazolines; Signal Transduction; Skin; Tyrosine; Up-Regulation | 2003 |
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomedical Research; Drug Design; Drug Industry; Drugs, Investigational; Endothelial Growth Factors; Erlotinib Hydrochloride; Germany; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasms; Pyrroles; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Clinical Trials in Cancer-SMi Conference. 11-12 June 2003, London, UK.
Topics: Antineoplastic Agents; Camptothecin; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Molecular Structure; Neoplasms; Quinazolines; Treatment Outcome | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
Topics: Biomarkers, Tumor; Bronchi; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Cyclin D1; DNA; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Exons; G1 Phase; Gastrointestinal Neoplasms; Gastrointestinal Tract; Humans; Immunoblotting; Immunohistochemistry; Ki-67 Antigen; Kinetics; Luciferases; Necrosis; Neoplasms; Quinazolines; Sequence Analysis, DNA; Time Factors; Transcriptional Activation | 2004 |
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2005 |
Association of skin rash and tumor response to HER1/EGFR inhibition: does HER1 stimulated tumor growth depend on circulatory instead of paracrine ligands?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autocrine Communication; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Ligands; Models, Biological; Neoplasm Proteins; Neoplasms; Paracrine Communication; Quinazolines; Skin; Transforming Growth Factor alpha; Treatment Outcome | 2005 |
[Cutaneous side effects of EGF-receptor inhibition and their management].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic | 2006 |
Epidermal growth factor receptor inhibitors: a moving target?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Highlights from the International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, And Clinical Applications, Philadelphia, PA, November 2005; ECCO 13--The European Cancer Conference, Paris, France, October 30-November 3, 2005.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Humans; Kinesins; Male; Neoplasms; Quinazolines; Vinblastine | 2005 |
[Current status and prospect of neoplasm targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Design; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Palliative Care; Piperazines; Pyrimidines; Quinazolines; Signal Transduction | 2005 |
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, fos; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasms; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2006 |
Researchers may use cancer cell lines to identify target populations prior to clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Quinazolines; Trastuzumab | 2006 |
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Cohort Studies; Data Interpretation, Statistical; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gastrointestinal Tract; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design | 2006 |
[Epidermal growth factor receptor family and targeted anticancer therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Neoplasms; Quinazolines; Trastuzumab | 2006 |
New insights into oncogene addiction found.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
When you look matters: the effect of assessment schedule on progression-free survival.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Neoplasms; Population Surveillance; Quinazolines; Research Design; Statistics, Nonparametric; Time Factors | 2007 |
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
Topics: Adult; Aged; Base Sequence; Cluster Analysis; Databases, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutagenesis, Insertional; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines; Sequence Deletion; Smoking | 2007 |
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estradiol; Gefitinib; Humans; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Binding; Quinazolines | 2007 |
Finding clinical meaning in cancer data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Evidence-Based Medicine; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sample Size; Survival Analysis | 2007 |
Epidermal growth factor receptor inhibitors and hair.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair; Humans; Neoplasms; Quinazolines | 2008 |